4//SEC Filing
Sprague John M 4
Accession 0000899243-23-007726
CIK 0001492674other
Filed
Mar 8, 7:00 PM ET
Accepted
Mar 9, 4:00 PM ET
Size
14.1 KB
Accession
0000899243-23-007726
Insider Transaction Report
Form 4
Transactions
- Sale
Common Stock
2023-02-22$0.65/sh−1,545$1,004→ 5,502 total - Sale
Common Stock
2023-02-28$0.59/sh−1,148$677→ 7,268 total - Exercise/Conversion
Restricted Stock Units
2023-02-20−4,000→ 8,000 total→ Common Stock (4,000 underlying) - Exercise/Conversion
Restricted Stock Units
2023-02-24−2,914→ 2,914 total→ Common Stock (2,914 underlying) - Exercise/Conversion
Common Stock
2023-02-20+4,000→ 7,047 total - Exercise/Conversion
Common Stock
2023-02-24+2,914→ 8,416 total
Footnotes (4)
- [F1]Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
- [F2]The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person adopted by the reporting person on June 15, 2018.
- [F3]On February 20, 2022 the reporting person was granted 12,000 RSU's that vest in three equal annual installments commencing on February 20, 2023
- [F4]On February 24, 2021 the reporting person was granted 8,743 RSU's that vest in three equal annual installments commencing on February 24, 2022.
Documents
Issuer
T2 Biosystems, Inc.
CIK 0001492674
Entity typeother
Related Parties
1- filerCIK 0001730056
Filing Metadata
- Form type
- 4
- Filed
- Mar 8, 7:00 PM ET
- Accepted
- Mar 9, 4:00 PM ET
- Size
- 14.1 KB